source
- FDA probes cancer risk from Zolgensma gene therapy after post-marketing tumor reportsThe FDA has issued a safety communication indicating it is investigating reports of malignancies in patients treated with Zolgensma, the adeno‑associated virus gene therapy for spinal muscular atro…
- Marea Therapeutics reports promising Phase 2b results for MAR001 in hypertriglyceridemiaMarea Therapeutics, which recently merged with oncology firm Lisata Therapeutics, disclosed data from the first part of its phase 2b trial of the drug candidate MAR001. The study enrolled patients…Fierce Biotech · 7d agoPositive readoutPositive